The effects of drugs used to treat obesity on the autonomic nervous system

被引:28
作者
Hirsch, J [1 ]
Mackintosh, RM [1 ]
Aronne, LJ [1 ]
机构
[1] Rockefeller Univ, Human Behav & Metab Lab, New York, NY 10021 USA
来源
OBESITY RESEARCH | 2000年 / 8卷 / 03期
关键词
autonomic nervous system; anti-obesity drugs; dexfenfluramine; phentermine; sibutramine;
D O I
10.1038/oby.2000.26
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Body fatness is partly under hypothalamic control with effector limbs, which include the endocrine system and the autonomic nervous system (ANS). In previous stud ies we have shown, in both obese and never-obese subjects, that weight increase leads to increased sympathetic and decreased parasympathetic activity, whereas weight decrease leads to decreased sympathetic and increased parasympathetic activity. We now report on the involvement of such ANS mechanisms in the action of anti-obesity drugs, independent of change in weight. Research Methods and Procedures: Normal weight males (ages 22 to 38 years) were fed a solid food diet, carefully measured to maintain body weight, for at least 2 weeks, as inpatients at the Rockefeller University General Clinical Research Center. In a single-blind, placebo/drug/placebo design, eight subjects received dexfenfluramine, seven phentermine (PHE), and seven sibutramine (SIB). ANS measures of parasympathetic and sympathetic activity included: determination of amount of parasympathetic control (PC) and sympathetic control (SC) of heart period (interbeat interval), using sequential pharmacological blockade by intravenous administration of atropine and esmolol. These autonomic controls of heart period are used to estimate the overall level of parasympathetic and sympathetic activities. Norepinephrine, dopamine, and epinephrine levels in 24-hour urine collections were measured and also resting metabolic rate (RMR). Results: Sufficient food intake maintained constant body weight in all groups. PHE and SIE produced significant increases in SC but no change in PC or in RMR. In contrast, dexfenfluramine produced marked decreases in SC, PC, and RMR. For all three drugs, the effects on urine catecholamines directly paralleled changes in cardiac measures of SC. Discussion: ANS responses to PHE and SIE were anticipated. The large, and unanticipated, response to dexfenfluramine suggests further study to determine whether there could be any relation of these ANS changes to the adverse cardiovascular effects of treatment with dexfenfluramine.
引用
收藏
页码:227 / 233
页数:7
相关论文
共 14 条
[1]   Appetite-suppressant drugs and the risk of primary pulmonary hypertension [J].
Abenhaim, L ;
Moride, Y ;
Brenot, F ;
Rich, S ;
Benichou, J ;
Kurz, X ;
Higenbottam, T ;
Oakley, C ;
Wouters, E ;
Aubier, M ;
Simonneau, G ;
Begaud, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (09) :609-616
[2]   HEMODYNAMIC, METABOLIC AND ENDOCRINE EFFECTS OF SHORT-TERM DEXFENFLURAMINE TREATMENT IN YOUNG, OBESE WOMEN [J].
ANDERSSON, B ;
ZIMMERMANN, ME ;
HEDNER, T ;
BJORNTORP, P .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (03) :249-254
[3]   AUTONOMIC NERVOUS-SYSTEM ACTIVITY IN WEIGHT-GAIN AND WEIGHT-LOSS [J].
ARONNE, LJ ;
MACKINTOSH, R ;
ROSENBAUM, M ;
LEIBEL, RL ;
HIRSCH, J .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1995, 269 (01) :R222-R225
[4]   Cardiac autonomic nervous system activity in obese and never-obese young men [J].
Aronne, LJ ;
Mackintosh, R ;
Rosenbaum, M ;
Leibel, RL ;
Hirsch, J .
OBESITY RESEARCH, 1997, 5 (04) :354-359
[5]   Valvular heart disease associated with fenfluramine-phentermine [J].
Connolly, HM ;
Crary, JL ;
McGoon, MD ;
Hensrud, DD ;
Edwards, BS ;
Edwards, WD ;
Schaff, HV .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09) :581-588
[6]   5-HT3 serotonin hetero-receptors inhibit [H-3]acethylcholine release in rat cortical synaptosomes [J].
Crespi, D ;
Gobbi, M ;
Mennini, T .
PHARMACOLOGICAL RESEARCH, 1997, 35 (04) :351-354
[7]  
HARRIS JA, 1919, CARNEGIE I WASHINGTO, V279, P40
[8]  
Linden AS, 1996, AM J VET RES, V57, P896
[9]   DEXFENFLURAMINE - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC POTENTIAL IN OBESITY [J].
MCTAVISH, D ;
HEEL, RC .
DRUGS, 1992, 43 (05) :713-733
[10]   Cholinergic/serotonergic interactions in hypothermia: Implications for rat models of depression [J].
Overstreet, DH ;
Daws, LC ;
Schiller, GD ;
Orbach, J ;
Janowsky, DS .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1998, 59 (04) :777-785